Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crescent BiopharmaFRA:C68 -2.40%18 12-1 Month Momentum % is 13.36% as of Sep. 11, 2026. GuruFocus rates FRA:C68 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 1,357 Biotechnology companies, Crescent Biopharma ranks better than 80.4% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-11), Crescent Biopharma's 12-1 Month Momentum % is 13.36%.
The industry rank for Crescent Biopharma's 12-1 Month Momentum % or its related term are showing as below:
FRA:C68's 12-1 Month Momentum % is ranked better than 80.4% of 1357
companies
in the Biotechnology industry
Industry Median: -19.89
vs FRA:C68: 13.36
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Crescent Biopharma 12-1 Month Momentum % Related Terms
FRA:C68 vs SGMT, MDXG, PRME: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Crescent Biopharma's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescent Biopharma 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crescent Biopharma's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Crescent Biopharma's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescent Biopharma (FRA:C68) has a 12-1 Month Momentum % of 13.36% as of Sep. 11, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Crescent Biopharma and its competitors. According to the industry distribution chart, Crescent Biopharma ranks #266 out of 1357 companies in the Biotechnology industry, placing it in the top 19.6%.
Is Crescent Biopharma's 12-1 Month Momentum % too high?
Crescent Biopharma's current 12-1 Month Momentum % is 13.36%. Based on the distribution chart, Crescent Biopharma ranks #266 out of 1357 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Crescent Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's 12-1 Month Momentum % compare to SGMT and MDXG?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #266 out of 1357 companies for 12-1 Month Momentum %. This places Crescent Biopharma in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current 12-1 Month Momentum % is 13.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current 12-1 Month Momentum % of 13.36%. The current 12-1 Month Momentum % is 13.36%. Crescent Biopharma's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current 12-1 Month Momentum % is 13.36% as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
18GF Score
Get the complete analysis for FRA:C68
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C68 has been successfully added to your 
